Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV-TR criteria for a primary diagnosis of ADHD~* Baseline ADHD-RS-IV score \>=28~* BP w/in 95th percentile for age, gender, and height~Exclusion Criteria:~* Subject has controlled or uncontrolled comorbid psychiatric diagnosis~* Subject has conduct disorder~* Suicidal~* Under or overweight~* Concurrent chronic or acute illness that might confound results.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine Dimesylate (LDX) 30 mg (Type: ACTIVE_COMPARATOR): None
- LDX 50 mg (Type: ACTIVE_COMPARATOR): None
- LDX 70 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).